Evidence map›Paper›PMID 31464934›Full record

ArticleMedicine2019

Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin resistance: Protocol for a systematic review.

Yinshan Wang, Aihua Yan, Shanshan Li, Bei Liu, Huimin Li, Yong Yan

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Nutrients · 2019
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yinshan WangDepartment of Endocrinology, Kaifeng Hospital of Traditional Chinese Medicine, Kaifeng.
Aihua YanHenan University of Chinese Medicine, Zhengzhou, China.
Shanshan LiHenan University of Chinese Medicine, Zhengzhou, China.
Bei LiuHenan University of Chinese Medicine, Zhengzhou, China.
Huimin LiHenan University of Chinese Medicine, Zhengzhou, China.
Yong YanDepartment of Endocrinology, Kaifeng Hospital of Traditional Chinese Medicine, Kaifeng.
First Affiliated Hospital of Henan University · CNKaifeng University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of diabetes mellitus (DM) is increasing year by year, and various complications can endanger the lives of patients. Type 2 diabetes mellitus (T2DM) accounts for more than 90% of DM, most of which is associated with insulin resistance (IR), and IR has been shown to be closely related to the onset of T2DM and the presence of DM complications. Berberine (BBR) has been shown to improve T2DM with IR in a number of ways. In this study, we aim to evaluate the efficacy and safety of BBR in the treatment of T2DM with IR to provide the newest evidence for clinical use. METHODS AND ANALYSIS: Literature research will be divided into 2 parts: electronic search and manual search. We will search PubMed, EMBASE, The Cochrane Library, the China National Knowledge Infrastructure, China Biology Medicine disc, the China Science and Technology Journal database, and the Wanfang database online. We will select the eligible studies published up to June 30, 2019. Dissertations, conference papers, ongoing trials, internal reports, etc., are searched by manual search methods. We use Homeostatic Model Assessment for IR (HOMA-IR) as the primary outcome of T2DM with IR, and we will also focus on the patient's blood glucose levels and all adverse reactions that occur during medication.Two reviewers will read the articles, extract the data information, and assess the risk of bias independently. Data analysis will use the software such as RevMan 5.3.5, ENDNOTE X7, and STATA 13.0.

resultsThis study will provide a high-quality synthesis of current evidence of BBR for T2DM with IR from several aspects including HOMA-IR, blood glucose levels, and adverse events.

conclusionThis systematic review will provide evidence to assess the efficacy and safety of BBR in the treatment of T2DM with IR. ETHICS AND DISSEMINATION: Because all of the data used in this systematic review has been published, ethical approval is not required. TRIAL REGISTRATION NUMBER: PROSPERO CRD42019123225.

Indexed as

Research DesignBerberineBlood GlucoseChinaDiabetes Mellitus, Type 2HumansInsulin ResistanceRandomized Controlled Trials as TopicSystematic Reviews as TopicBerberineBlood Glucose

Identifiers

PMID31464934
PMCPMC6736273
OpenAlexW2971077062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.